The Best RAC-US Exam Study Material Premium Files and Preparation Tool (Jul-2022)
Get Instant Access to RAC-US Practice Exam Questions
NEW QUESTION 30
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class D
- B. Class C
- C. Class B
- D. Class A
Answer: B
NEW QUESTION 31
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Plasma pooling
- B. Product distribution
- C. Individual plasma donation
- D. Plasma fractionation
Answer: B
NEW QUESTION 32
During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?
- A. All senior management from the main office
- B. As many as government attendees
- C. The minimum number of attendees necessary to address the issues
- D. As many as required by international standards
Answer: C
NEW QUESTION 33
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Communicate with the relevant internal departments.
- B. Prepare documents for the files.
- C. Request a permanent waiver from the new regulation.
- D. Contact the trade association for advice.
Answer: A
NEW QUESTION 34
What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?
- A. Ask the vendor to take responsibility.
- B. Request documentation from the sub-contractor.
- C. Request an inspection from a regulatory authority.
- D. Document and perform audits.
Answer: D
NEW QUESTION 35
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Consult with the company's legal department regarding options.
- B. Arrange for additional testing of the product at the testing facility.
- C. Obtain a copy of the proposed regulation and analyze the impact.
- D. Inform the company's senior management and arrange an emergency meeting
Answer: C
NEW QUESTION 36
Which of the following BEST describes the process of post-marketing surveillance for healthcare products?
- A. Vigilance procedure to notify the regulatory authorities about serious incidents
- B. Vigilance procedure to ensure the full traceability of the products
- C. Systematic procedure to review published scientific journals
- D. Systematic procedure to review experiences with the products in use
Answer: B
NEW QUESTION 37
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform either an identification study or a non-clinical qualification study.
- B. Perform both identification and non-clinical qualification studies concurrently.
- C. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
- D. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
Answer: D
NEW QUESTION 38
Which of the following BEST describes the purpose of the ICH?
- A. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- B. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
- C. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- D. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
Answer: A
NEW QUESTION 39
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release. - B. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
- C. Ask that the regulatory authority provide the actual product subject to the complaint.
- D. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
Answer: B
NEW QUESTION 40
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed dose and volume of administration
- B. Immunochemical and functional tests
- C. Proposed product route and frequency of administration
- D. Biological activity with species and/or tissue specificity
Answer: D
NEW QUESTION 41
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
- A. Phase I and II clinical trials
- B. Phase III clinical trials
- C. Pre-clinical studies
- D. Phase I clinical trials
Answer: B
NEW QUESTION 42
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is effective for the treatment of arthritis."
- B. "Product X is safe for arthritis and without side effects."
- C. "Product X is effective in all patients with arthritis."
- D. "Product X is a guaranteed cure for arthritis."
Answer: A
NEW QUESTION 43
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and records due to confidentiality concerns.
- B. Allow the auditor access to the room and records due to the current audit.
- C. Deny the auditor access to the room and retrieve only the requested records.
- D. Allow the auditor accompanied access to the room to retrieve the records.
Answer: D
NEW QUESTION 44
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: B
NEW QUESTION 45
A company is considering the development of a medical device similar to those already available. Which of the following should be evaluated FIRST when developing a clinical evaluation document?
- A. Literature search
- B. Clinical experience
- C. Adverse event reports
- D. Clinical investigations
Answer: D
NEW QUESTION 46
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Compatibility and safety
- B. Volume and material
- C. Safety and efficacy
- D. Efficacy and material
Answer: A
NEW QUESTION 47
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. Until the product has been discontinued from marketing in all ICH regions
- B. For a minimum of 10 years after completion of the clinical study
- C. For at least two years after the last approval of an application in an ICH region
- D. Three years after the last clinical study site was supplied with investigational drugs
Answer: C
NEW QUESTION 48
Which of the following claims would classify an apple as a drug?
- A. "It will prevent colds."
- B. "It will satisfy hunger."
- C. "It will make you look younger."
- D. "It will whiten teeth."
Answer: A
NEW QUESTION 49
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Regulatory agency
- B. Clinical affairs
- C. Quality assurance
- D. Quality improvement
Answer: C
NEW QUESTION 50
......
Validate your Skills with Updated RAC-US Exam Questions & Answers and Test Engine: https://certkingdom.pass4surequiz.com/RAC-US-exam-quiz.html